Baseline characteristics among patients with cytotoxic CTCL
| Characteristic . | N = 18 (100%) . |
|---|---|
| Sex, n (%) | |
| Female | 8.0 (44.4) |
| Male | 10.0 (55.6) |
| Race/ethnicity, n (%) | |
| African American | 3.0 (16.7) |
| American Indian/Alaskan Native | 1.0 (5.6) |
| Asian | 6.0 (33.3) |
| White | 8.0 (44.4) |
| Diagnosis, n (%) | |
| CD8+ PCAETL | 3.0 (16.7) |
| PCGDTL | 6.0 (33.3) |
| SPTCL | 9.0 (50.0) |
| Age at cancer diagnosis (y), n (%) | |
| <40 | 4.0 (22.2) |
| 40-64 | 7.0 (38.9) |
| ≥65 | 7.0 (38.9) |
| Cutaneous ulceration, n (%) | |
| No | 11.0 (61.1) |
| Yes | 7.0 (38.9) |
| HLH, n (%) | |
| No | 8.0 (44.4) |
| Yes | 10.0 (55.6) |
| Extracutaneous involvement, n (%) | |
| No | 5.0 (27.8) |
| Yes | 10.0 (55.6) |
| Prior lines of therapy, n (%) | |
| 0 | 4.0 (22.2) |
| 1 | 11.0 (61.1) |
| 2 | 1.0 (5.6) |
| 4 | 2.0 (11.1) |
| Characteristic . | N = 18 (100%) . |
|---|---|
| Sex, n (%) | |
| Female | 8.0 (44.4) |
| Male | 10.0 (55.6) |
| Race/ethnicity, n (%) | |
| African American | 3.0 (16.7) |
| American Indian/Alaskan Native | 1.0 (5.6) |
| Asian | 6.0 (33.3) |
| White | 8.0 (44.4) |
| Diagnosis, n (%) | |
| CD8+ PCAETL | 3.0 (16.7) |
| PCGDTL | 6.0 (33.3) |
| SPTCL | 9.0 (50.0) |
| Age at cancer diagnosis (y), n (%) | |
| <40 | 4.0 (22.2) |
| 40-64 | 7.0 (38.9) |
| ≥65 | 7.0 (38.9) |
| Cutaneous ulceration, n (%) | |
| No | 11.0 (61.1) |
| Yes | 7.0 (38.9) |
| HLH, n (%) | |
| No | 8.0 (44.4) |
| Yes | 10.0 (55.6) |
| Extracutaneous involvement, n (%) | |
| No | 5.0 (27.8) |
| Yes | 10.0 (55.6) |
| Prior lines of therapy, n (%) | |
| 0 | 4.0 (22.2) |
| 1 | 11.0 (61.1) |
| 2 | 1.0 (5.6) |
| 4 | 2.0 (11.1) |